| Help | About | Contact Us

Publication : Preclinical evaluation of a COVID-19 vaccine candidate based on a recombinant RBD fusion heterodimer of SARS-CoV-2.

First Author	Barreiro A	Year	2023
Journal	iScience	Volume	26
Issue	3	Pages	106126
PubMed ID	36748086	Mgi Jnum	J:335993
Mgi Id	MGI:7433866	Doi	10.1016/j.isci.2023.106126
Citation	Barreiro A, et al. (2023) Preclinical evaluation of a COVID-19 vaccine candidate based on a recombinant RBD fusion heterodimer of SARS-CoV-2. iScience :106126

abstractText

Current COVID-19 vaccines have been associated with a decline in infection rates, prevention of severe disease and a decrease in mortality rates. However, SARS-CoV-2 variants are continuously evolving, and development of new accessible COVID-19 vaccines is essential to mitigate the pandemic. Here, we present data on preclinical studies in mice of a receptor-binding domain (RBD)-based recombinant protein vaccine (PHH-1V) consisting of an RBD fusion heterodimer comprising the B.1.351 and B.1.1.7 SARS-CoV-2 variants formulated in SQBA adjuvant, an oil-in-water emulsion. A prime-boost immunisation with PHH-1V in BALB/c and K18-hACE2 mice induced a CD4(+) and CD8(+) T cell response and RBD-binding antibodies with neutralising activity against several variants, and also showed a good tolerability profile. Significantly, RBD fusion heterodimer vaccination conferred 100% efficacy, preventing mortality in SARS-CoV-2 infected K18-hACE2 mice, but also reducing Beta, Delta and Omicron infection in lower respiratory airways. These findings demonstrate the feasibility of this recombinant vaccine strategy.

Your name:
Your email address:
Subject:
Message:	---- Current page: ---- /mousemine/report.do?id=76675426

MouseMine

Publication : Preclinical evaluation of a COVID-19 vaccine candidate based on a recombinant RBD fusion heterodimer of SARS-CoV-2.

External Links

Expression

Publication --> Expression annotations

Other

46 Authors

4 Bio Entities

0 Expression